Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 5;12(9):128.
doi: 10.1038/s41408-022-00717-2.

High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis

Jahanzaib Khwaja  1 , Joshua Bomsztyk  2 , Shameem Mahmood  2 , Brendan Wisniowski  2 , Raakhee Shah  1 , Anish Tailor  1 , Kwee Yong  1 , Rakesh Popat  1 , Neil Rabin  1 , Charalampia Kyriakou  1 , Jonathan Sive  1 , Simona Degli Esposti  3 , Daniel F P Larkin  3 , Sarah Worthington  1 , Alyse Hart  1 , Emma Dowling  1 , Nuno Correia  1 , Ceri Bygrave  4 , Andrzej Rydzewski  5 , Krzysztof Jamroziak  6 , Ashutosh D Wechalekar  7
Affiliations

High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis

Jahanzaib Khwaja et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

JK, JB, SM, BW, RS, AT, CK, JS, SDE, DFPL, SW, AH, ED, NC, CB, KJ: no conflict of interest. KY: BMS research funding; Amgen honoraria; GSK honoraria; Takeda honoraria; Janssen honoraria, research funding; Sanofi honoraria, research funding; Autolus research funding. RP: AbbVie, BMS, Janssen, Oncopeptides, and Amgen honoraria; Takeda honoraria; GlaxoSmithKline consultancy, honoraria, research funding; Abbvie, Takeda, Janssen, and Celgene consultancy; Janssen and BMS travel expenses; NR: BMS/Celgene consultancy, honoraria, travel support for meetings; Takeda consultancy, honoraria, travel support for meetings; Janssen: consultancy, honoraria, travel support for meetings; AR: honoraria (for invited lectures) and travel grants Astellas, Fresenius, Sandoz; ADW: Amgen research funding; Alexion, AstraZeneca rare disease consultancy; Caelum Biosciences: clinical trial funding; Janssen consultancy; Takeda honoraria; Celgene honoraria.

Figures

Fig. 1
Fig. 1. Treatment response rates.
a Overall response rates; b Time to treatment response; Key: CR complete response, VGPR very good partial response, NR no response, ORR overall response rate.
See this image and copyright information in PMC

References

    1. Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207–21. doi: 10.1016/S1470-2045(19)30788-0. - DOI - PubMed
    1. Zhang Y, Godara A, Pan S, Toskic D, Fogaren T, Sborov DW, et al. Belantamab mafadotin in patients with relapsed/refractory AL amyloidosis with myeloma. Blood. 2021;138(Suppl 1):1670. doi: 10.1182/blood-2021-151365. - DOI
    1. Rezk T, Lachmann HJ, Fontana M, Sachchithanantham S, Mahmood S, Petrie A, et al. Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor. Kidney Int. 2017;92:1476–83. doi: 10.1016/j.kint.2017.05.004. - DOI - PubMed
    1. Palladini G, Schönland SO, Sanchorawala V, Kumar S, Wechalekar A, Hegenbart U, et al. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid. 2021;28:1–2. doi: 10.1080/13506129.2020.1868810. - DOI - PubMed
    1. Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol Ther. 2020;9:889–911. doi: 10.1007/s40123-020-00280-8. - DOI - PMC - PubMed

Publication types